These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15294941)

  • 1. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent.
    Nanni P; Landuzzi L; Nicoletti G; De Giovanni C; Rossi I; Croci S; Astolfi A; Iezzi M; Di Carlo E; Musiani P; Forni G; Lollini PL
    J Immunol; 2004 Aug; 173(4):2288-96. PubMed ID: 15294941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
    Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
    Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
    Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
    J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.
    De Giovanni C; Nicoletti G; Palladini A; Croci S; Landuzzi L; Antognoli A; Murgo A; Astolfi A; Ferrini S; Fabbi M; Orengo AM; Amici A; Penichet ML; Aurisicchio L; Iezzi M; Musiani P; Nanni P; Lollini PL
    Hum Gene Ther; 2009 May; 20(5):453-64. PubMed ID: 19215191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
    Cappello P; Triebel F; Iezzi M; Caorsi C; Quaglino E; Lollini PL; Amici A; Di Carlo E; Musiani P; Giovarelli M; Forni G
    Cancer Res; 2003 May; 63(10):2518-25. PubMed ID: 12750275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
    Park JM; Terabe M; Sakai Y; Munasinghe J; Forni G; Morris JC; Berzofsky JA
    J Immunol; 2005 Apr; 174(7):4228-36. PubMed ID: 15778385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
    Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
    Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
    Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
    J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice.
    Venanzi FM; Barucca A; Havas K; Capitani M; Provinciali M; Scotti S; Concetti A
    Vaccine; 2010 May; 28(22):3841-7. PubMed ID: 20350624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
    Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
    Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.